TSAAI 2018 Annual Meeting

Pigeon Forge, TN US
August 3, 2018 to August 5, 2018

This meeting focuses on concerns and educational needs of allergists and immunologists.  Topics include: food allergy, atopic dermatitis and immunotherapy. Both national and regional thought leaders will provide an outstanding educational opportunity to all attendees.

 

 

Target Audience

Practicing allergists and allied healthcare providers in the field of allergy and immunology.
 

 

 

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Tennessee Society of Allergy, Asthma & Immunology (TSAAI) .  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Funding

This activity is not supported by educational grants.

 

 

 

 

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Analyze risk factors contributing to pediatric asthma and immunotherapy treatment
  • Appraise the current data regarding food immunotherapy
  • Recognize when and how to treat patients with new biologics
  • Explain the four components of ABAI Maintenance of Certification (MOC) and how to complete the Continuous Assessment Program
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships to disclose must also inform the learners that no financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

 

All identified conflicts of interest have been resolved.

 

Michael Blaiss, MD (Speaker): Consultant/Consulting Fee – Pfizer, JDP Therapeutics, Sanofi/Regeneron, Stallergenes/Greer;  Consultant/Speaker/Honorarium -  ALK; Consultant/Consulting Fee/Honorarium - PMD Healthcare, Boston Scientific

 

Mark Corbett, MD (Speaker): Consultant/Consulting Fee - Kaleo, Inc., Pharming, Inc;  Speaker -  OptiNose

 

Jay Lieberman, MD (Speaker): Advisory Board/Honorarium -  Aimmune, DBV Technologies

 

Gailen Marshall, Jr, MD, PhD (Speaker): Research Support-  AstraZeneca 

 

John Oppenheimer, MD (Speaker): Consultant -  GSK, AstraZeneca, DBV, Regeneron, Sanofi, Teva, Kaleo

 

The following have no relevant financial relationships to disclose:

Monica Lawrence, MD (Speaker)

Phil Lieberman, MD (Speaker)

Karthik Krishnan, MD (Program Chair)

Reba Green (Meeting Coordinator)

 

Course summary
Available credit: 
  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Course opens: 
08/03/2018
Course expires: 
08/05/2020
Event starts: 
08/03/2018 - 4:00pm CDT
Event ends: 
08/05/2018 - 11:30am CDT
Add to calendar: 
Rating: 
0
Dollywood DreamMore Conference Center
2525 DreamMore Way
Pigeon Forge, TN 37863
United States
+1 (800) 365-5996

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Tennessee Society of Allergy, Asthma & Immunology (TSAAI) .  The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Designation

The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 7.00 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 7.00 AMA PRA Category 1 Credit™
  • 7.00 Attendance
Please login or create an account to take this course.